Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.

Pharmacological research - 1 Dec 2022

Xie Ying, Feng Sen-Ling, He Fang, Yan Pei-Yu, Yao Xiao-Jun, Fan Xing-Xing, Leung Elaine Lai-Han, Zhou Hua

Abstract excerpt

Multiple drug resistance (MDR) is the major obstacle for both chemotherapy and molecular-targeted therapy for cancer, which is mainly caused by overexpression of ABC transporters or genetic mutation of drug targets. Based on previous studies, we hypothesized that ROS/Nrf2 is the common target for overcoming acquired drug resistance to both targeted therapy and chemotherapy treatments. In this study, we firstly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Multiple

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to NF-E2-Related Factor 2

Share to Paclitaxel

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Reactive Oxygen Species

Source

Identifiers

PMID: 36252771
DOI: 10.1016/j.phrs.2022.106514

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.PMID 36252771Read ↗

[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].Semantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.Semantic proximity Read ↗

Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathwaysSemantic proximity Read ↗

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read ↗

NRF-mediated autophagy and UPR: Exploring new avenues to overcome cancer chemo-resistanceSemantic proximity Read ↗

Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.Semantic proximity Read ↗

Role of NRF2 cascade in determining the differential response of cervical cancer cells to anticancer drugs- an in vitro studySemantic proximity Read ↗

The Dual Roles of NRF2 in Cancer.Semantic proximity Read ↗

The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cellsSemantic proximity Read ↗

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cellsSemantic proximity Read ↗

[Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.